We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Diagnostics Intends to Form Strategic Partnership with CapitalBio

By LabMedica International staff writers
Posted on 30 Nov 2010
Roche Diagnostics (Basel, Switzerland) and China's premier biochip development company, CapitalBio (Beijing, China) announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. More...


The new development builds on the genomics and diagnostics expertise of the two companies and it will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

The partnership plans to focus initially on the research and development of instruments and products to enhance and automate the Roche NimbleGen microarray workflow and the application of this workflow in preventive and personalized diagnostics.

Special focus shall be placed on cooperation in education on the benefits and use of molecular diagnostics that exploit novel technologies involving microarrays and their related products, and next-generation sequencing in both the greater China and international markets. The partnership also plans to establish educational facilities across China for molecular R&D and the application of clinical molecular diagnostics.

"CapitalBio and Roche offer a large number of complementary skills and interests which can be well served through the harnessing of the capabilities of both companies for product research and development, manufacturing, marketing, and distribution in China and for international markets,” said Professor Jing Cheng, CEO of CapitalBio.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

CapitalBio Corporation is China's leading developer and marketer of diagnostic biochips, microarray related instruments, and microarray services. Its range of LuxScan laser confocal microarray scanners, microarray spotters, and related microarray workflow instruments are used widely in many countries. Its active biochips for cell biology studies and dedicated software for data analysis and biomedical data management are also being used increasingly for clinical studies, including oncology studies.

Related Links:

Roche
CapitalBio




New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.